4th In Vivo Cell Engineering & Gene Editing Summit

R&D
4th In Vivo Cell Engineering & Gene Editing Summit

The 4th In Vivo Cell Engineering & Gene Editing Summit, taking place June 3–5, 2025 in Boston, is the definitive event dedicated to advancing next-generation in vivo cell and gene therapies from early research to clinical and commercial reality.

As the industry pivots from ex vivo to in vivo strategies to improve scalability, accessibility, and cost-effectiveness, this forum brings together the brightest minds from biopharma, academia, and regulatory leadership to explore the full translational journey, from delivery platform selection to IND-enabling studies and first-in-human data.

Across three immersive days, gain direct insights from 20+ pioneering speakers including Gilmore O’Neill (Editas Medicine), Robert Peters (Ensoma), Safi Shahda (Intellia Therapeutics), Dana Foss (Editpep), Maurits Geerlings (NanoCell Therapeutics), and John Rossi (Capstan Therapeutics). These experts will unpack key challenges and breakthroughs in delivery, targeting, manufacturing, clinical development, and so much more.

Here’s what to expect from the 2025 edition:

  • Compare viral vs. non-viral delivery systems (including LNPs, LVVs, AAVs, and protein-based platforms) for safety, potency, and precision
  • Address regulatory gaps and explore evolving global IND and preclinical model requirements
  • Access real-world first-in-human data from in vivo CAR and gene editing trials
  • Dive into immune evasion, liver de-targeting, and off-target toxicity reduction strategies
  • Leverage insights into transgene insertion vs. transient expression to guide delivery optimisation
  • Participate in two hands-on workshops: one focused on delivery model selection, the other on regulatory and preclinical evidence building

 

The agenda has been carefully shaped by experts with real-world experience to equip you with the critical knowledge needed to progress to the clinic. Whether you're designing payloads for extrahepatic targets, scaling up delivery platforms, or navigating the complexities of clinical trial design, the sessions offer practical insights grounded in industry reality. Featuring contributions from Sana Biotechnology, Beam Therapeutics, AbbVie, Delos Capital, and many more you'll gain actionable takeaways to sharpen your translational strategy and advance confidently toward the clinic.

 

Want to discover who else will be presenting at this summit or learn more about how this summit will support your path to the clinic? View the agenda: https://ter.li/zjvedj

IVCG